Navigation Links
Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives

SAN DIEGO, Sept. 2 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced the appointment of Patrick O'Connor, PhD, Vice President, Research, Michael J. LaBarre, PhD, Vice President, Product Development, and James E. Cartoni, Vice President, Legal.

"Halozyme is committed to attracting, developing, and retaining world- class talent. We are delighted that seasoned executives such as Patrick, Michael, and Jim have joined the team. Successfully recruiting executives of this caliber underscores our commitment to finding exceptional talent, and also reflects the high level of excitement Halozyme is generating in the biotech industry," said Jonathan Lim, MD, President and CEO of Halozyme Therapeutics. "Their broad collective experience in drug development, formulation, analytical methodology, manufacturing, and the legal aspects of biotechnology brings further breadth and depth to our leadership team. All three executives will work closely with our senior management to enable Halozyme to achieve its business objectives."

Patrick O'Connor's responsibilities will include leadership of Halozyme's multiple biology and chemistry research programs. Dr. O'Connor joins Halozyme from Ardea Biosciences where he was Senior Vice President and Chief Scientific Officer. Prior to joining Ardea, Dr. O'Connor served in various executive research positions at Pfizer Global Research & Development and Agouron Pharmaceuticals (now Pfizer, Inc.) from 1998 to 2007. His last position with Pfizer as Vice President, Research Therapeutic Area Head, Global Oncology, included responsibility for setting the overall global oncology research strategy and overseeing all aspects of oncology research. While at Pfizer, Dr. O'Connor also built and oversaw the diabetes and obesity research groups at the La Jolla campus. His managerial duties encompassed the generation of new drug targets, the selection of development candidates, and strategic and scientific support for Phase 1 and 2 clinical studies. Prior to joining Pfizer, Dr. O'Connor served as a Fogarty Fellow at The National Cancer Institute, Bethesda, Maryland from 1988 to 1998. He is on the Editorial Board of Cancer Research and is a member of numerous scientific and medical professional organizations. Dr. O'Connor received his BSc degree in Pharmacology from Bradford University, England, and his PhD in Experimental Oncology Therapeutics from Manchester University, England.

Michael J. LaBarre will oversee all of Halozyme's product development efforts, bringing strong experience in chemistry, manufacturing and controls (CMC) based on his extensive experience in the biotechnology industry for both biologics and small molecules. In his previous role as Vice President of Product Development at Paramount BioSciences, LLC, Dr. LaBarre led the CMC efforts for all of the product development programs within Paramount's portfolio. Prior to joining Paramount, Dr. LaBarre served in various research and development positions at Biogen Idec (previously IDEC) from 1995 to 2006 where he had responsibility for analytical and formulation development, protein purification, and biochemical characterization supporting numerous IND and BLA submissions, including those for Rituxan(R) and Zevalin(R). His last position with Biogen Idec was Director of Analytical and Protein Biochemistry. Prior to IDEC, Dr. LaBarre spent two years at Vical, Inc. in the analytical methods development group. He began his career at Hybritech where he held positions in regulatory affairs and manufacturing technical support, focusing on radiolabeled antibody technologies and analytical chemistry. Dr. LaBarre received his BS degree in Chemistry from Southampton College and his PhD in Bioinorganic Chemistry from the University of Arizona.

James E. Cartoni will oversee various legal matters, including the negotiation and completion of agreements, corporate governance matters, securities compliance, and the coordination and management of outside legal counsel. Prior to joining Halozyme, Mr. Cartoni was a partner at DLA Piper, the world's largest law firm, where he represented numerous public and private companies in areas such as financing transactions, corporate compliance, mergers & acquisitions and general business matters. DLA Piper is Halozyme's primary outside corporate counsel and Mr. Cartoni has represented Halozyme since 2004. Mr. Cartoni also served as the Co-Chair of the Legal and Finance Committee for the 2008 U.S. Open at Torrey Pines Golf Course. Mr. Cartoni obtained his BA degree in Political Science from Occidental College and his Juris Doctor degree from the University of California -- Hastings College of the Law in 1998.

About Halozyme Therapeutics, Inc.

Halozyme is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the drug delivery, metabolism, oncology, and dermatology markets. The company's portfolio of products and product candidates is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company's Enhanze(TM) Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. Its key partnerships are with Roche to apply Enhanze Technology to Roche's biological therapeutic compounds for up to 13 targets and with Baxter to apply Enhanze Technology to Baxter's biological therapeutic compound, GAMMAGARD LIQUID 10%. In addition, the company has received FDA approval for two products: Cumulase(R), for use in in-vitro fertilization, and HYLENEX, for use as an adjuvant to increase the absorption and dispersion of other injected drugs and fluids. HYLENEX is partnered with Baxter International Inc. Halozyme also has a number of different enzymes in its portfolio that target significant areas of unmet medical need. For more information visit

Safe Harbor Statement

In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements concerning the expected roles and responsibilities of management) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are also identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including regulatory approval requirements and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the company's reports on Forms 10-K, 10-Q, and other filings with the Securities and Exchange Commission.

Halozyme Contact Media Contacts

Robert H. Uhl Karen Sparks / Joleen Schultz

Senior Director, Investor Relations Mentus

(858) 704-8264 (858) 455-5500, x275/x215

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
2. Halozyme Therapeutics to Present at the Jefferies 2nd Annual Healthcare Conference
3. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
4. Halozyme Therapeutics to Hold Pipeline Update Conference Call on May 9
5. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
6. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
7. Halozyme Therapeutics to Hold Pipeline Update Conference Call on March 14
8. Halozyme Therapeutics to Present at the BIO CEO and Investor Conference and the Roth Growth Stock Conference
9. Halozyme Therapeutics Amends Stockholder Rights Plan
10. Halozyme Therapeutics Reports 2007 Third Quarter Financial Results
11. Halozyme Therapeutics to Present at UBS 2007 Global Life Sciences Conference
Post Your Comments:
(Date:11/25/2015)... November 25, 2015 Studies reveal ... human plaque and pave the way for more effective treatment ... cats     --> ... diagnosed health problems in cats, yet relatively little was understood ... collaborative studies have been conducted by researchers from the WALTHAM ...
(Date:11/25/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; TSX: ... prospects remain fundamentally strong and highlights the following ... received DSMB recommendation to continue the ZoptEC Phase ... the final interim efficacy and safety data ... men with heavily pretreated castration- and Taxane-resistant prostate ...
(Date:11/25/2015)... The Global Genomics Industry ... and in-depth study on the current state of ... ) , The report provides ... classifications, applications and industry chain structure. The Genomics ... including development trends, competitive landscape analysis, and key ...
(Date:11/24/2015)... N.J. (PRWEB) , ... November 24, 2015 , ... The ... the recipient of the 2016 USGA Green Section Award. Presented annually since 1961, the ... through his or her work with turfgrass. , Clarke, of Iselin, N.J., ...
Breaking Biology Technology:
(Date:11/2/2015)...  SRI International has been awarded a contract of ... to the National Cancer Institute (NCI) PREVENT Cancer Program ... modern testing and support facilities, and analytical instrumentation to ... studies to evaluate potential cancer prevention drugs. ... Drug Development Program is an NCI-supported pipeline to bring ...
(Date:10/29/2015)... Va. , Oct. 29, 2015 Daon, ... today that it has released a new version of ... customers in North America have ... IdentityX v4.0 also includes a FIDO UAF certified ... are already preparing to activate FIDO features. These customers ...
(Date:10/29/2015)... , October 29, 2015 ... biometric authentication company focused on the growing mobile ... wallet announces that StackCommerce, a leading marketplace to ... featuring the Wocket® smart wallet on StackSocial for ... ) ("NXT-ID" or the "Company"), a biometric authentication ...
Breaking Biology News(10 mins):